Aplidin Approved in Australia for Relapsed or Refractory Multiple Myeloma
Treatment with Aplidin (plitidepsin) in combination with…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
Triple Combo Therapy May Slow Smoldering Multiple Myeloma Progression into Overt Myeloma, Phase 2 Trial Shows
Early treatment with a triple combination therapy containing Empliciti…
Nonprofit Launches Trial to Get Therapies to Multiple Myeloma Patients More Efficiently
The Multiple Myeloma Research Foundation (MMRF) is launching…
Phase 2 Myeloma Trial for Investigational CAR T-cell Therapy bb2121 Completes Enrollment
An international Phase 2 trial testing the investigational CAR…
AMG 420 Immunotherapy Shows Promise in Relapsed or Refractory Multiple Myeloma
Results from the first in-human clinical trial assessing Amgen’s…
Researchers Identify 3 Genetic Alterations Associated with Higher Risk of Myeloma in African-Americans
Researchers have identified three genetic alterations associated with the…
